By combining their skills, resources and client base, the two young firms will feed off each other to create new opportunities.
PharmaScan, the clinical unit of the Dermscan Group, is quite unique in that it is both a CRO and a Clinical Investigation Center, carrying out phase I to IV trials on drugs and medical devices both on site at its clinical investigation centre in Lyon and also in doctors' surgeries and hospitals.
ClinicalLand, a general CRO based in Paris, will greatly benefit from the use of this Clinical Investigation Centre, as well as the 35,500 patients 100 specialist clinicians that PharmaScan has access to.
In addition, PharmaScan specialises in more unusual areas of clinical investigation, such as dermatology, gynaecology, odontostomatology and ophthalmology, adding to the more mainstream clinical areas of rheumatology, pneumoallergology, gastro-enterology, gynaecology and paediatrics that ClinicalLand currently covers.
On the other hand, ClinicalLand specialises in Relationship Management and a large base of investigators of over 6,000 clinicians in hospitals, generalists and specialists, from which PharmaScan will benefit.
"PharmaScan, via ClinicalLand, will be able to bolster its own structures, access an appropriate network of investigators specialising in highly diverse fields, and will also be able to optimise the management of multi-centre studies in new therapeutic areas," said a company statement.
The partnership also aims to strengthen the common areas of expertise that the two CROs have in common in the areas of biometry, such as data management, biostatistics and medical writing, as well as marketing and scientific communications, said the statement.
In 2005, PharmaScan had a turnover of €2.5m, while ClinicalLand achieved a turnover of €1.25m.With PharmaScan counting among its clients major pharma firms such as Arkopharma, Johnson & Johnson, Urgo, Merck Lifa, Novartis and the Sanofi Synthelabo Group, and ClinicalLand working with firms such as Air Liquide, Ciba Vision, Novartis, Pierre Fabre, Pfizer and Sanofi-Aventis, the two firms are now well positioned to improve their financial position in the future.